Quarterly report pursuant to Section 13 or 15(d)

EQUTY INVESTMENT (Details Narrative)

v3.19.1
EQUTY INVESTMENT (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended
Dec. 18, 2018
Mar. 31, 2019
Goodwill   $ 2,445,000
ILiAD [Member]    
Advisory and legal expenses   41,000
ILiAD [Member] | Maximum [Member]    
Investment $ 5,000,000  
ILiAD [Member] | Tranche One [Member]    
Initial investment $ 2,500,000  
Description for the terms of allowed-to-proceed notice under aggrement On May 2, 2019, ILiAD notified the Company that it had received an "allowed to proceed" notice from the FDA permitting ILiAD to advance to the Phase 2b clinical study of its BP2E1 vaccine. ILiAD elected to permit its Class C investors (including the Company) to bifurcate their tranche 2 commitments such that 40% would be currently due (additional $1,000,000 investment by the Company which was made on May 6, 2019) and 60% (additional $1,500,000 investment by the Company) would be due when ILiAD receives satisfactory safety data from the clinical study.  
ILiAD [Member] | Tranche Two [Member]    
Initial investment   $ 2,500,000
ILiAD [Member] | Class C units [Member] | Maximum [Member]    
Investment $ 16,200,000  
ILiAD [Member] | Class C units [Member] | Tranche One [Member]    
Units purchase   1,111,111
Price per unit   $ 2.25
Warrants to purchase units   366,666
Exercise price   $ 2.75
Ownership percentage   6.80%
ILiAD [Member] | Class C units [Member] | Tranche Two [Member]    
Units purchase 943,396  
Price per unit $ 2.65  
Warrants to purchase units 311,320  
Exercise price $ 3.50  
Ownership percentage 10.50%